About the Company
Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc. Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.In 2014, Catalent became a public company, listed on the New York Stock Exchange.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CTLT News
A New Cause for Concern: Catalent Inc Adds a New Share Price & Shareholder Rights Risk
Catalent Inc (CTLT) has disclosed a new risk, in the Share Price & Shareholder Rights category. Catalent Inc. faces a ...
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
If you own shares of Catalent, Inc. click here . Is the Proposed Acquisition Best for Catalent, Inc. (CTLT) and its Shareholders? On February 2, 2024, the companies announced a merger agreement under ...
Catalent, Inc. (CTLT)
After the deal closes, it would sell three of Catalent's fill-finish sites on to Novo Nordisk for $11 billion. (Bloomberg) -- Ares Management Corp. and Blue Owl Capital Inc. are leading a group of ...
Catalent Stock (NYSE:CTLT), Analyst Ratings, Price Targets, Predictions
$55.78-22.91% Wells Fargo ...
Catalent Pharma Solutions, Inc.
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs
MADISON, Wis., April 02, 2024--(BUSINESS WIRE)--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global ...
Catalent, Inc. (0C8.F)
Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall ...
Catalent Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Catalent Inc.
Invest with your heart and your phone with as little as $1 with these ESG and socially responsible investing apps.
Loading the latest forecasts...